Darras BT. Spinal muscular atrophies. Pediatr Clin North Am. 2015;62(3):743–66.

Article  PubMed  Google Scholar 

Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831–46.

Article  PubMed  PubMed Central  Google Scholar 

Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–65.

Article  CAS  PubMed  Google Scholar 

Prior TW, Leach ME, Finanger E. Spinal muscular atrophy. In: Adam MP, et al., editors. GeneReviews®. Seattle, WA: University of Washington; 1993.

Google Scholar 

Biogen Inc. SPINRAZA® (nusinersen) US prescribing information. December 2016. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf. Accessed Apr 2024.

Novartis Gene Therapies, Inc. ZOLGENSMA® (onasemnogene abeparvovec-xioi) US prescribing information. December 2023. https://www.novartis.com/us-en/sites/novartis_us/files/zolgensma.pdf. Accessed Apr 2024.

US Food and Drug Administration. EVRYSDI™ highlights of prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213535s000lbl.pdf. Accessed Apr 2024.

Cure SMA. FDA approves Genentech’s Evrysdi (risdiplam) for use in babies under two months with spinal muscular atrophy. 2022. https://www.curesma.org/fda-approves-genentechs-evrysdi-risdiplam-for-use-in-babies-under-two-months-with-spinal-muscular-atrophy/. Accessed Apr 2024.

Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy—new phenotypes, new challenges, new implications for care. J Neuromuscul Dis. 2020;7(1):1–13.

Article  PubMed  PubMed Central  Google Scholar 

Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103–15.

Article  PubMed  Google Scholar 

Sumner CJ, Crawford TO. Early treatment is a lifeline for infants with SMA. Nat Med. 2022;28(7):1348–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Masson R, Mazurkiewicz-Beldzinska M, Rose K, et al. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. Lancet Neurol. 2022;21(12):1110–9.

Article  CAS  PubMed  Google Scholar 

Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–32.

Article  CAS  PubMed  Google Scholar 

Day JW, Finkel RS, Chiriboga CA, et al. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284–93.

Article  CAS  PubMed  Google Scholar 

Łusakowska A, Wójcik A, Frączek A, et al. Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience. Orphanet J Rare Dis. 2023;18(1):230.

Article  PubMed  PubMed Central  Google Scholar 

Ñungo Garzón NC, Pitarch Castellano I, Sevilla T, Vázquez-Costa JF. Risdiplam in non-sitter patients aged 16 years and older with 5q spinal muscular atrophy. Muscle Nerve. 2023;67(5):407–11.

Article  PubMed  Google Scholar 

Sitas B, Hancevic M, Bilic K, Bilic H, Bilic E. Risdiplam real world data—looking beyond motor neurons and motor function measures. J Neuromuscular Dis. 2023;11:75–84.

Article  Google Scholar 

Kakazu J, Walker NL, Babin KC, et al. Risdiplam for the use of spinal muscular atrophy. Orthop Rev (Pavia). 2021;13(2):25579.

Article  PubMed  Google Scholar 

Weaver MS, Yuroff A, Sund S, Hetzel S, Halanski MA. Quality of life outcomes according to differential nusinersen exposure in pediatric spinal muscular atrophy. Children (Basel). 2021;8(7):604.

PubMed  Google Scholar 

Gauthier-Loiselle M, Cloutier M, Toro W, et al. Nusinersen for spinal muscular atrophy in the United States: findings from a retrospective claims database analysis. Adv Ther. 2021;38(12):5809–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fox D, To TM, Seetasith A, Patel AM, Iannaccone ST. Adherence and persistence to nusinersen for spinal muscular atrophy: a US claims-based analysis. Adv Ther. 2022;40(3):903–19.

Article  PubMed  PubMed Central  Google Scholar 

Youn B, Proud CM, Wang N, et al. Examining real-world adherence to nusinersen for the treatment of spinal muscular atrophy using two large US data sources. Adv Ther. 2023;40(3):1129–40.

Article  PubMed  PubMed Central  Google Scholar 

Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O. Economic burden of spinal muscular atrophy in the United States: a contemporary assessment. J Med Econ. 2020;23(1):70–9.

Article  PubMed  Google Scholar 

Monette A, Chen E, Bazzano A, Dixon S, David Arnold W, Shi L. Treatment preference among patients with spinal muscular atrophy (SMA): a discrete choice experiment. Orphanet J Rare Dis. 2021;16:36.

Article  Google Scholar 

Canfield SL, Zuckerman A, Anguiano RH, et al. Navigating the Wild West of medication adherence reporting in specialty pharmacy. J Manage Care Spec Pharm. 2019;25(10):1073–7.

Google Scholar 

Engmann NJ, Sheinson D, Bawa K, Ng CD, Pardo G. Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data. J Manage Care Spec Pharm. 2021;27(5):639–49.

Google Scholar 

Pardo G, Pineda ED, Ng CD, Bawa KK, Sheinson D, Bonine NG. Adherence to and persistence with disease-modifying therapies for multiple sclerosis over 24 months: a retrospective claims analysis. Neurol Ther. 2022;11(1):337–51.

Article  PubMed  PubMed Central  Google Scholar 

Kozma CM, Dickson M, Phillips AL, Meletiche DM. Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis. Patient Prefer Adher. 2013;7:509–16.

Article  Google Scholar 

Powell JC, Meiling JB, Cartwright MS. A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy. Muscle Nerve. 2023;69(2):179–84.

Article  PubMed  Google Scholar 

Xiao L, Kang S, Djordjevic D, et al. Understanding caregiver experiences with disease-modifying therapies for spinal muscular atrophy: a qualitative study. Arch Dis Child. 2023;108(11):929–34.

Article  PubMed  Google Scholar 

Gusset N, Stalens C, Stumpe E, et al. Understanding European patient expectations towards current therapeutic development in spinal muscular atrophy. Neuromuscul Disord. 2021;31(5):419–30.

Article  PubMed  Google Scholar 

Wan HWY, Carey KA, D'Silva A, Kasparian NA, Farrar MA. “Getting ready for the adult world”: how adults with spinal muscular atrophy perceive and experience healthcare, transition and well-being. Orphanet J Rare Dis. 2019;14(1):74.

Article  PubMed  PubMed Central  Google Scholar 

Michelson D, Ciafaloni E, Ashwal S, et al. Evidence in focus: Nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology. 2018;91(20):923–33.

Article  PubMed  Google Scholar 

Zingariello CD, Brandsema J, Drum E, et al. A multidisciplinary approach to dosing nusinersen for spinal muscular atrophy. Neurol Clin Pract. 2019;9(5):424–32.

Article  PubMed  PubMed Central  Google Scholar 

Chen E, Dixon S, Naik R, et al. Early experiences of nusinersen for the treatment of spinal muscular atrophy: results from a large survey of patients and caregivers. Muscle Nerve. 2021;63(3):311–9.

Article  PubMed  Google Scholar 

Cordts I, Lingor P, Friedrich B, et al. Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy. Ther Adv Neurol Disord. 2020;13:1756286419887616.

Article  PubMed  PubMed Central  Google Scholar 

Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012;73(5):691–705.

Article  PubMed  PubMed Central  Google Scholar 

Elman L, Youn B, Proud CM, et al. Real-world adherence to nusinersen in adults with spinal muscular atrophy in the US: a multi-site chart review study. J Neuromuscul Dis. 2022;9(5):655–60.

Article  PubMed  PubMed Central  Google Scholar 

Lam, WY, Fresco, P. Medication Adherence Measures: An Overview. Biomed Res Int, 2015. 2015: p. 217047

Wilder ME, Kulie P, Jensen C, et al. The impact of social determinants of health on medication adherence: a systematic review and meta-analysis. J Gen Intern Med. 2021;36(5):1359–70.

Article  PubMed  PubMed Central  Google Scholar 

Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.

Article  CAS  PubMed  Google Scholar 

Osborn CY, Kripalani S, Goggins KM, Wallston KA. Financial strain is associated with medication nonadherence and worse self-rated health among cardiovascular patients. J Health Care Poor Underserved. 2017;28(1):499–513.

Article  PubMed  PubMed Central  Google Scholar 

DiMatteo MR, Haskard KB, Williams SL. Health beliefs, disease severity, and patient adherence: a meta-analysis. Med Care. 2007;45(6):521–8.

Article  PubMed  Google Scholar